Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 47 entries
Sorted by: Best Match Show Resources per page
(1)H NMR spectral simplification with achiral and chiral lanthanide shift reagents. Tranylcypromine, trans-2-phenylcyclopropanamine.

Journal of pharmaceutical and biomedical analysis

Hatzis A, Rothchild R.
PMID: 16867581
J Pharm Biomed Anal. 1986;4(4):451-9. doi: 10.1016/0731-7085(86)80066-8.

The 60 MHz (1)H NMR spectra of racemic tranylcypromine, 1, have been studied with the achiral shift reagent, tris(6,6,7,7,8,8,8-heptafluoro-2,2-dimethyl-3,5-octanedionato) europium(III), 2, and the chiral tris[3-(trifluoromethylhydroxymethylene)-d-camphorato] europium(III), 3. Appreciable values of the enantiomeric shift differences, DeltaDeltadelta, were observed for each...

Cite
Hatzis A, Rothchild R. (1)H NMR spectral simplification with achiral and chiral lanthanide shift reagents. Tranylcypromine, trans-2-phenylcyclopropanamine. J Pharm Biomed Anal. 1986;4(4):451-9doi: 10.1016/0731-7085(86)80066-8.
Hatzis, A., & Rothchild, R. (1986). (1)H NMR spectral simplification with achiral and chiral lanthanide shift reagents. Tranylcypromine, trans-2-phenylcyclopropanamine. Journal of pharmaceutical and biomedical analysis, 4(4), 451-9. https://doi.org/10.1016/0731-7085(86)80066-8
Hatzis, A, and Rothchild, R. "(1)H NMR spectral simplification with achiral and chiral lanthanide shift reagents. Tranylcypromine, trans-2-phenylcyclopropanamine." Journal of pharmaceutical and biomedical analysis vol. 4,4 (1986): 451-9. doi: https://doi.org/10.1016/0731-7085(86)80066-8
Hatzis A, Rothchild R. (1)H NMR spectral simplification with achiral and chiral lanthanide shift reagents. Tranylcypromine, trans-2-phenylcyclopropanamine. J Pharm Biomed Anal. 1986;4(4):451-9. doi: 10.1016/0731-7085(86)80066-8. PMID: 16867581.
Copy Download .nbib Format: NLM
Fluorinated phenylcyclopropylamines. Part 6: Effects of electron withdrawing or donating aryl substituents on the inhibition of tyramine oxidase from Arthrobacter sp. by diastereomeric 2-aryl-2-fluoro-cyclopropylamines.

Journal of fluorine chemistry

Hruschka S, Yoshida S, Kirk KL, Haufe G.
PMID: 19727324
J Fluor Chem. 2008 Sep;129(9):875-880. doi: 10.1016/j.jfluchem.2008.06.023.

Diastereomeric arylcyclopropylamines substituted with fluorine in the 2-position and with electron donating or electron withdrawing groups at the aromatic ring were evaluated as inhibitors of microbial tyramine oxidase. The trans-isomers were consistently more potent inhibitors of the enzyme than...

Cite
Hruschka S, Yoshida S, Kirk KL, et al. Fluorinated phenylcyclopropylamines. Part 6: Effects of electron withdrawing or donating aryl substituents on the inhibition of tyramine oxidase from Arthrobacter sp. by diastereomeric 2-aryl-2-fluoro-cyclopropylamines. J Fluor Chem. 2008;129(9):875-880doi: 10.1016/j.jfluchem.2008.06.023.
Hruschka, S., Yoshida, S., Kirk, K. L., & Haufe, G. (2008). Fluorinated phenylcyclopropylamines. Part 6: Effects of electron withdrawing or donating aryl substituents on the inhibition of tyramine oxidase from Arthrobacter sp. by diastereomeric 2-aryl-2-fluoro-cyclopropylamines. Journal of fluorine chemistry, 129(9), 875-880. https://doi.org/10.1016/j.jfluchem.2008.06.023
Hruschka, Svenja, et al. "Fluorinated phenylcyclopropylamines. Part 6: Effects of electron withdrawing or donating aryl substituents on the inhibition of tyramine oxidase from Arthrobacter sp. by diastereomeric 2-aryl-2-fluoro-cyclopropylamines." Journal of fluorine chemistry vol. 129,9 (2008): 875-880. doi: https://doi.org/10.1016/j.jfluchem.2008.06.023
Hruschka S, Yoshida S, Kirk KL, Haufe G. Fluorinated phenylcyclopropylamines. Part 6: Effects of electron withdrawing or donating aryl substituents on the inhibition of tyramine oxidase from Arthrobacter sp. by diastereomeric 2-aryl-2-fluoro-cyclopropylamines. J Fluor Chem. 2008 Sep;129(9):875-880. doi: 10.1016/j.jfluchem.2008.06.023. PMID: 19727324; PMCID: PMC2598398.
Copy Download .nbib Format: NLM
Use of tranylcypromine in severe resistant depression : a case report.

Indian journal of psychiatry

Maulik PK, Das S, Saxena S.
PMID: 21455381
Indian J Psychiatry. 1999 Apr;41(2):163-7.

This case report describes the improvement obtained by using tranylcypromine in a patient of severe treatment resistant depression. The adverse effects faced and steps taken to overcome them have also been discussed.

Cite
Maulik PK, Das S, Saxena S. Use of tranylcypromine in severe resistant depression : a case report. Indian J Psychiatry. 1999;41(2):163-7
Maulik, P. K., Das, S., & Saxena, S. (1999). Use of tranylcypromine in severe resistant depression : a case report. Indian journal of psychiatry, 41(2), 163-7.
Maulik, P K, et al. "Use of tranylcypromine in severe resistant depression : a case report." Indian journal of psychiatry vol. 41,2 (1999): 163-7.
Maulik PK, Das S, Saxena S. Use of tranylcypromine in severe resistant depression : a case report. Indian J Psychiatry. 1999 Apr;41(2):163-7. PMID: 21455381; PMCID: PMC2962842.
Copy Download .nbib Format: NLM
Brain-penetrant LSD1 inhibitors can block memory consolidation.

ACS chemical neuroscience

Neelamegam R, Ricq EL, Malvaez M, Patnaik D, Norton S, Carlin SM, Hill IT, Wood MA, Haggarty SJ, Hooker JM.
PMID: 22754608
ACS Chem Neurosci. 2012 Feb 15;3(2):120-128. doi: 10.1021/cn200104y. Epub 2011 Oct 18.

Modulation of histone modifications in the brain may represent a new mechanism for brain disorder therapy. Post-translational modifications of histones regulate gene expression, affecting major cellular processes such as proliferation, differentiation, and function. An important enzyme involved in one...

Cite
Neelamegam R, Ricq EL, Malvaez M, et al. Brain-penetrant LSD1 inhibitors can block memory consolidation. ACS Chem Neurosci. 2011;3(2):120-128doi: 10.1021/cn200104y.
Neelamegam, R., Ricq, E. L., Malvaez, M., Patnaik, D., Norton, S., Carlin, S. M., Hill, I. T., Wood, M. A., Haggarty, S. J., & Hooker, J. M. (2012). Brain-penetrant LSD1 inhibitors can block memory consolidation. ACS chemical neuroscience, 3(2), 120-128. https://doi.org/10.1021/cn200104y
Neelamegam, Ramesh, et al. "Brain-penetrant LSD1 inhibitors can block memory consolidation." ACS chemical neuroscience vol. 3,2 (2012): 120-128. doi: https://doi.org/10.1021/cn200104y
Neelamegam R, Ricq EL, Malvaez M, Patnaik D, Norton S, Carlin SM, Hill IT, Wood MA, Haggarty SJ, Hooker JM. Brain-penetrant LSD1 inhibitors can block memory consolidation. ACS Chem Neurosci. 2012 Feb 15;3(2):120-128. doi: 10.1021/cn200104y. Epub 2011 Oct 18. PMID: 22754608; PMCID: PMC3382965.
Copy Download .nbib Format: NLM
Tranylcypromine Causes Neurotoxicity and Represses BHC110/LSD1 in Human-Induced Pluripotent Stem Cell-Derived Cerebral Organoids Model.

Frontiers in neurology

Huang J, Liu F, Tang H, Wu H, Li L, Wu R, Zhao J, Wu Y, Liu Z, Chen J.
PMID: 29270148
Front Neurol. 2017 Dec 07;8:626. doi: 10.3389/fneur.2017.00626. eCollection 2017.

Recent breakthroughs in human pluripotent stem cell-derived cerebral organoids provide a valuable platform for investigating the human brain after different drugs treatments and for understanding the complex genetic background to human pathology. Here, we identified tranylcypromine, which is used...

Cite
Huang J, Liu F, Tang H, et al. Tranylcypromine Causes Neurotoxicity and Represses BHC110/LSD1 in Human-Induced Pluripotent Stem Cell-Derived Cerebral Organoids Model. Front Neurol. 2017;8:626doi: 10.3389/fneur.2017.00626.
Huang, J., Liu, F., Tang, H., Wu, H., Li, L., Wu, R., Zhao, J., Wu, Y., Liu, Z., & Chen, J. (2017). Tranylcypromine Causes Neurotoxicity and Represses BHC110/LSD1 in Human-Induced Pluripotent Stem Cell-Derived Cerebral Organoids Model. Frontiers in neurology, 8626. https://doi.org/10.3389/fneur.2017.00626
Huang, Jing, et al. "Tranylcypromine Causes Neurotoxicity and Represses BHC110/LSD1 in Human-Induced Pluripotent Stem Cell-Derived Cerebral Organoids Model." Frontiers in neurology vol. 8 (2017): 626. doi: https://doi.org/10.3389/fneur.2017.00626
Huang J, Liu F, Tang H, Wu H, Li L, Wu R, Zhao J, Wu Y, Liu Z, Chen J. Tranylcypromine Causes Neurotoxicity and Represses BHC110/LSD1 in Human-Induced Pluripotent Stem Cell-Derived Cerebral Organoids Model. Front Neurol. 2017 Dec 07;8:626. doi: 10.3389/fneur.2017.00626. eCollection 2017. PMID: 29270148; PMCID: PMC5725435.
Copy Download .nbib Format: NLM
HFIP-Promoted de Novo Synthesis of Biologically Relevant Nonnatural α-Arylated Amino Esters and Dipeptide Mimetics.

Chemistry (Weinheim an der Bergstrasse, Germany)

Li Z, Yu B.
PMID: 31617627
Chemistry. 2019 Oct 16; doi: 10.1002/chem.201904395. Epub 2019 Oct 16.

Amino acids are fundamental building blocks, which have been extensively used in drug design and organic synthesis. However, nonnatural amino acids are relatively less studied. In this work, the authors report the first HFIP-promoted de novo synthesis of nonnatural...

Cite
Li Z, Yu B. HFIP-Promoted de Novo Synthesis of Biologically Relevant Nonnatural α-Arylated Amino Esters and Dipeptide Mimetics. Chemistry. 2019;doi: 10.1002/chem.201904395.
Li, Z., & Yu, B. (2019). HFIP-Promoted de Novo Synthesis of Biologically Relevant Nonnatural α-Arylated Amino Esters and Dipeptide Mimetics. Chemistry (Weinheim an der Bergstrasse, Germany), . https://doi.org/10.1002/chem.201904395
Li, Zhonghua, and Yu, Bin. "HFIP-Promoted de Novo Synthesis of Biologically Relevant Nonnatural α-Arylated Amino Esters and Dipeptide Mimetics." Chemistry (Weinheim an der Bergstrasse, Germany) vol. (2019). doi: https://doi.org/10.1002/chem.201904395
Li Z, Yu B. HFIP-Promoted de Novo Synthesis of Biologically Relevant Nonnatural α-Arylated Amino Esters and Dipeptide Mimetics. Chemistry. 2019 Oct 16; doi: 10.1002/chem.201904395. Epub 2019 Oct 16. PMID: 31617627.
Copy Download .nbib Format: NLM
Repurposing antidepressants for anticancer drug discovery.

Drug discovery today

Song Y, Yang X, Yu B.
PMID: 34728374
Drug Discov Today. 2021 Oct 30; doi: 10.1016/j.drudis.2021.10.019. Epub 2021 Oct 30.

Drug repurposing is an attractive strategy for identifying new indications for existing drugs. Three approved antidepressants have advanced into clinical trials for cancer therapy. In particular, further medicinal chemistry efforts with tranylcypromine (TCP) have led to the discovery of...

Cite
Song Y, Yang X, Yu B. Repurposing antidepressants for anticancer drug discovery. Drug Discov Today. 2021;doi: 10.1016/j.drudis.2021.10.019.
Song, Y., Yang, X., & Yu, B. (2021). Repurposing antidepressants for anticancer drug discovery. Drug discovery today, . https://doi.org/10.1016/j.drudis.2021.10.019
Song, Yihui, et al. "Repurposing antidepressants for anticancer drug discovery." Drug discovery today vol. (2021). doi: https://doi.org/10.1016/j.drudis.2021.10.019
Song Y, Yang X, Yu B. Repurposing antidepressants for anticancer drug discovery. Drug Discov Today. 2021 Oct 30; doi: 10.1016/j.drudis.2021.10.019. Epub 2021 Oct 30. PMID: 34728374.
Copy Download .nbib Format: NLM
Cardiovascular Effects of Combining Subcutaneous or Intravenous Esketamine and the MAO Inhibitor Tranylcypromine for the Treatment of Depression: A Retrospective Cohort Study.

CNS drugs

Ludwig VM, Sauer C, Young AH, Rucker J, Bauer M, Findeis H, Ritter P.
PMID: 34283390
CNS Drugs. 2021 Aug;35(8):881-892. doi: 10.1007/s40263-021-00837-6. Epub 2021 Jul 20.

BACKGROUND: (Es)ketamine and monoamine oxidase inhibitors (MAOIs), e.g., tranylcypromine, are therapeutic options for treatment-resistant major depression. Simultaneous administration is currently not recommended because of concern about hypertensive crises.OBJECTIVE: Our objective was to evaluate whether changes in systolic blood pressure...

Cite
Ludwig VM, Sauer C, Young AH, et al. Cardiovascular Effects of Combining Subcutaneous or Intravenous Esketamine and the MAO Inhibitor Tranylcypromine for the Treatment of Depression: A Retrospective Cohort Study. CNS Drugs. 2021;35(8):881-892doi: 10.1007/s40263-021-00837-6.
Ludwig, V. M., Sauer, C., Young, A. H., Rucker, J., Bauer, M., Findeis, H., & Ritter, P. (2021). Cardiovascular Effects of Combining Subcutaneous or Intravenous Esketamine and the MAO Inhibitor Tranylcypromine for the Treatment of Depression: A Retrospective Cohort Study. CNS drugs, 35(8), 881-892. https://doi.org/10.1007/s40263-021-00837-6
Ludwig, Vera M, et al. "Cardiovascular Effects of Combining Subcutaneous or Intravenous Esketamine and the MAO Inhibitor Tranylcypromine for the Treatment of Depression: A Retrospective Cohort Study." CNS drugs vol. 35,8 (2021): 881-892. doi: https://doi.org/10.1007/s40263-021-00837-6
Ludwig VM, Sauer C, Young AH, Rucker J, Bauer M, Findeis H, Ritter P. Cardiovascular Effects of Combining Subcutaneous or Intravenous Esketamine and the MAO Inhibitor Tranylcypromine for the Treatment of Depression: A Retrospective Cohort Study. CNS Drugs. 2021 Aug;35(8):881-892. doi: 10.1007/s40263-021-00837-6. Epub 2021 Jul 20. PMID: 34283390; PMCID: PMC8354966.
Copy Download .nbib Format: NLM
An Update of Lysine Specific Demethylase 1 Inhibitor: A Patent Review (2016-2020).

Recent patents on anti-cancer drug discovery

Zheng YC, Liu YJ, Gao Y, Wang B, Liu HM.
PMID: 34323202
Recent Pat Anticancer Drug Discov. 2021 Jul 28; doi: 10.2174/1574892816666210728125224. Epub 2021 Jul 28.

BACKGROUND: As a FAD (Flavin Adenine Dinucleotide) - dependent histone demethylase discovered in 2004, LSD1 (lysine specific demethylase 1) was reported to be overexpressed in diverse tumors, regulating target genes transcription associated with cancer development. Hence, LSD1 targeted inhibitors...

Cite
Zheng YC, Liu YJ, Gao Y, et al. An Update of Lysine Specific Demethylase 1 Inhibitor: A Patent Review (2016-2020). Recent Pat Anticancer Drug Discov. 2021;doi: 10.2174/1574892816666210728125224.
Zheng, Y. C., Liu, Y. J., Gao, Y., Wang, B., & Liu, H. M. (2021). An Update of Lysine Specific Demethylase 1 Inhibitor: A Patent Review (2016-2020). Recent patents on anti-cancer drug discovery, . https://doi.org/10.2174/1574892816666210728125224
Zheng, Yi-Chao, et al. "An Update of Lysine Specific Demethylase 1 Inhibitor: A Patent Review (2016-2020)." Recent patents on anti-cancer drug discovery vol. (2021). doi: https://doi.org/10.2174/1574892816666210728125224
Zheng YC, Liu YJ, Gao Y, Wang B, Liu HM. An Update of Lysine Specific Demethylase 1 Inhibitor: A Patent Review (2016-2020). Recent Pat Anticancer Drug Discov. 2021 Jul 28; doi: 10.2174/1574892816666210728125224. Epub 2021 Jul 28. PMID: 34323202.
Copy Download .nbib Format: NLM
Pharmacological and Neuromodulatory Treatments for Panic Disorder: Clinical Trials from 2010 to 2018.

Psychiatry investigation

Zugliani MM, Cabo MC, Nardi AE, Perna G, Freire RC.
PMID: 30696238
Psychiatry Investig. 2019 Jan;16(1):50-58. doi: 10.30773/pi.2018.12.21.1. Epub 2019 Jan 25.

OBJECTIVE: Treatment for panic disorder (PD) have evolved, although there is still a strong unmet need for more effective and tolerable options. The present study summarizes and discusses recent evidence regarding the pharmacological and neuromodulatory treatment of PD.METHODS: MEDLINE,...

Cite
Zugliani MM, Cabo MC, Nardi AE, et al. Pharmacological and Neuromodulatory Treatments for Panic Disorder: Clinical Trials from 2010 to 2018. Psychiatry Investig. 2019;16(1):50-58doi: 10.30773/pi.2018.12.21.1.
Zugliani, M. M., Cabo, M. C., Nardi, A. E., Perna, G., & Freire, R. C. (2019). Pharmacological and Neuromodulatory Treatments for Panic Disorder: Clinical Trials from 2010 to 2018. Psychiatry investigation, 16(1), 50-58. https://doi.org/10.30773/pi.2018.12.21.1
Zugliani, Morena M, et al. "Pharmacological and Neuromodulatory Treatments for Panic Disorder: Clinical Trials from 2010 to 2018." Psychiatry investigation vol. 16,1 (2019): 50-58. doi: https://doi.org/10.30773/pi.2018.12.21.1
Zugliani MM, Cabo MC, Nardi AE, Perna G, Freire RC. Pharmacological and Neuromodulatory Treatments for Panic Disorder: Clinical Trials from 2010 to 2018. Psychiatry Investig. 2019 Jan;16(1):50-58. doi: 10.30773/pi.2018.12.21.1. Epub 2019 Jan 25. PMID: 30696238; PMCID: PMC6354041.
Copy Download .nbib Format: NLM
Pharmacotherapy of dysthymia: review and new findings.

European psychiatry : the journal of the Association of European Psychiatrists

Versiani M, Nardi AE, Figueira I.
PMID: 19698626
Eur Psychiatry. 1998 Jul;13(4):203-9. doi: 10.1016/S0924-9338(98)80005-9.

Open trials with tricyclics, classical monoamine oxidase inhibitors (MAOIs) or lithium in dysthymia yielded a response rate in 45% of subjects. A long-term treatment of dysthymia with 276 patients treated during 4 years with either moclobemide, tranylcypromine or a...

Cite
Versiani M, Nardi AE, Figueira I. Pharmacotherapy of dysthymia: review and new findings. Eur Psychiatry. 1998;13(4):203-9doi: 10.1016/S0924-9338(98)80005-9.
Versiani, M., Nardi, A. E., & Figueira, I. (1998). Pharmacotherapy of dysthymia: review and new findings. European psychiatry : the journal of the Association of European Psychiatrists, 13(4), 203-9. https://doi.org/10.1016/S0924-9338(98)80005-9
Versiani, M, et al. "Pharmacotherapy of dysthymia: review and new findings." European psychiatry : the journal of the Association of European Psychiatrists vol. 13,4 (1998): 203-9. doi: https://doi.org/10.1016/S0924-9338(98)80005-9
Versiani M, Nardi AE, Figueira I. Pharmacotherapy of dysthymia: review and new findings. Eur Psychiatry. 1998 Jul;13(4):203-9. doi: 10.1016/S0924-9338(98)80005-9. PMID: 19698626.
Copy Download .nbib Format: NLM
Clinical Evaluation of a New Antidepressant Agent: Tranylcypromine with Trifluoperazine (Parstelin).

Canadian Medical Association journal

Straker M.
PMID: 20326565
Can Med Assoc J. 1960 Dec 17;83(25):1306-10.

No abstract available.

Cite
Straker M. Clinical Evaluation of a New Antidepressant Agent: Tranylcypromine with Trifluoperazine (Parstelin). Can Med Assoc J. 1960;83(25):1306-10
Straker, M. (1960). Clinical Evaluation of a New Antidepressant Agent: Tranylcypromine with Trifluoperazine (Parstelin). Canadian Medical Association journal, 83(25), 1306-10.
Straker, M. "Clinical Evaluation of a New Antidepressant Agent: Tranylcypromine with Trifluoperazine (Parstelin)." Canadian Medical Association journal vol. 83,25 (1960): 1306-10.
Straker M. Clinical Evaluation of a New Antidepressant Agent: Tranylcypromine with Trifluoperazine (Parstelin). Can Med Assoc J. 1960 Dec 17;83(25):1306-10. PMID: 20326565; PMCID: PMC1939035.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 47 entries